Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05967715
Other study ID # MicroFit
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 3, 2023
Est. completion date April 2, 2026

Study information

Verified date July 2023
Source University of Bologna
Contact Davide Agnoletti, PhD
Phone 00390512145597
Email davide.agnoletti2@unibo.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cardiovascular diseases are the number 1 cause of death globally, taking an estimated 17.9 million lives each year (31% of deaths worldwide). Hypertension, with 1.13 billion people affected worldwide, is the leading risk factor for global mortality. Physical inactivity is among the modifiable cardiovascular risk factors. While the beneficial effects of physical activity on cardiovascular system are widely known, the mechanisms involved are not completely understood. Both exercise training and hypertension are linked to inflammation. Furthermore, there is evidence that gut microbiota regulates inflammatory patterns. Recent investigations showed a relationship between exercise training and the composition/functionality of the gut microbiota. Anyway, the modification of the composition and functionality of the gut microbiota in hypertension due to the exercise training and the relative involvement of oxidative stress and inflammation are not completely understood. In literature an association between gut microbiota composition and arterial stiffness is described, in particular, the investigators observed both a direct correlation between arterial stiffness and abundances of bacteria associated with altered gut permeability and inflammation; and an inverse relationship between arterial stiffness, microbiota diversity, and abundances of bacteria associated with most fit microbiota composition. Anyway, while these association were stable in animal studies, in human studies none of the identified interventional trials was able to demonstrate this relationship. Of note, only half of human studies measured BP, and very few adjusted the vascular analyses for BP variation, which is a major determinant of arterial stiffness. This is a non-profit, monocentric, non-pharmacological interventional study, a randomized controlled trial with three intervention arms, partial double-blind, aiming to verify the hypothesis that, in hypertensive patients in primary prevention with cardiovascular risk factors, physical exercise favorably modifies the intestinal bacterial flora compared to the probiotic, with a positive impact on cardiovascular health, and to demonstrate that this involves inflammation modulation. There will be 3 intervention arms, with 1:1:1 stratified randomization by gender: 1. Administration of controlled physical activity training; 2. Administration of probiotic; 3. Administration of placebo. Arms 2 and 3 will be double-blind. The intervention will last for three months, followed by a 6-month follow-up period. Afterwards, the medical team may be contacted for further tests/assessments or simply for information about the participant's health status, for a total duration of 24 months. The investigators hypothesize that hypertensive patients in cardiovascular primary prevention have a dysbiotic gut microbial signatures, that could be a new marker of early vascular aging. Secondly, the investigators anticipate that exercise training will modify both gut microbiota and hemodynamic profile, and that a relationship exists between gut microbiota and hemodynamic modifications. Thirdly, the investigators expect that the beneficial effects of exercise training are driven by positive changes in the inflammatory modulators.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date April 2, 2026
Est. primary completion date April 2, 2026
Accepts healthy volunteers No
Gender All
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: - Arterial hypertension*; - Stable antihypertensive therapy in the last 2 months, with controlled blood pressure values; - Age 40-65 years; - Willing to sign the written informed consent; - Written and spoken Italian language comprehension. Exclusion Criteria: - Atrial fibrillation; - Diabetes mellitus either type I or II; - Active cancer; - Inflammatory bowel disease; - Heart failure NYHA class III to IV; - Recent antibiotic or probiotic treatment in the previous month for any reason; - Recent myocardial infarction or hospital admission for any other reason in the previous 6 months; - Any other condition that the medical doctor (MD) considers to contraindicate the participation in an exercise program of High intensity; - Pulmonary disease requiring oxygen therapy; - Relevant neurological condition impairing motor or cognitive function; - Severe depressive disorder; - Pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
exercise training
high intensity interval training
Other:
Probiotics
VSL#3# Probiotic
Placebo
Probiotic Placebo

Locations

Country Name City State
Italy University of Bologna Bologna

Sponsors (2)

Lead Sponsor Collaborator
University of Bologna Actial Farmaceutica S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary To describe the modification of the gut microbiota composition and function after the exercise training compared to probiotic supplements and to placebo. Changes in measures of gut microbiota composition and function from time 0 to 3 months (alpha diversity, beta diversity, taxonomy, relative abundance of microbial genes and pathways) time 0 and 3 months
Secondary To describe the association between gut microbiota patterns with impaired central hemodynamics To measure the association of gut microbiota diversity indexes, taxonomy, relative abundance of microbial genes and pathways, with central hemodynamics parameters (central blood pressure, aortic stiffness, pulse pressure amplification, augmentation index). time 0 and 3 months
Secondary To test the association of the systemic inflammation with the modification of gut microbiota composition/functionality. To test the association between inflammatory markers (alpha-1-acid glycoprotein, high-sensitive c-reactive protein) and gut microbiota diversity indexes, taxonomy, relative abundance of microbial genes and pathways. time 0 and 3 months
Secondary To test the modification of endothelial function after the exercise training in comparison to probiotic supplements and placebo. To measure variation in endothelial glycocalyx thickness before and after 3-mo intervention time 0, and 3 months
Secondary To identify the variation of the gut microbiota composition and function in the long term follow up after the intervention Measures of gut microbiota diversity indexes, taxonomy, relative abundance of microbial genes and pathways at the end of the intervention (3 months) and after the 9-mo follow up. from 3 to 9 months.
Secondary To describe the association between gut microbiota patterns with impaired central hemodynamics in the long term follow up 6 months after the intervention To measure the association of gut microbiota diversity indexes, taxonomy, relative abundance of microbial genes and pathways, with central hemodynamics parameters (central blood pressure, aortic stiffness, pulse pressure amplification, augmentation index) at 9-mo follow up
Secondary To test the association of the systemic inflammation with the modification of gut microbiota composition/functionality, after the long term follow up 6 months after the intervention. To test the association between inflammatory markers (alpha-1-acid glycoprotein, high-sensitive c-reactive protein) and gut microbiota diversity indexes, taxonomy, relative abundance of microbial genes and pathways, at 9-mo follow up. at 9-mo follow up
Secondary To test the modification of endothelial function after the exercise training in comparison to probiotic supplements and placebo, after the long term follow up 6 months after the intervention To measure variation in endothelial glycocalyx thickness at 9-mo follow up at 9-mo follow up
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A